Understanding precisely how enteroviruses hijack human cells has long been hampered by a fundamental blind spot: no one could directly observe the moment a viral particle opens and releases its genetic payload inside a living system. That gap has now narrowed considerably, with implications for antiviral drug design targeting a family of viruses responsible for meningitis, myocarditis, and hand-foot-and-mouth disease.
Using cryo-electron microscopy and in vivo imaging approaches, researchers characterized the structural transition by which echovirus 18 — a member of the enterovirus family — physically opens its protein capsid to discharge its RNA genome into the host cell environment. The study, published in PNAS, identified specific conformational changes in the icosahedral capsid, including the formation of expanded or 'A-particle' intermediate states, that precede full genome ejection. Critically, these transitions were observed in a living biological context rather than reconstructed from detergent-treated or heat-shocked particles in vitro, lending the findings substantially greater physiological relevance.
Enteroviruses have historically resisted mechanistic scrutiny at this stage of infection because the uncoating event is transient, spatially confined, and structurally heterogeneous. Most prior structural data came from artificially induced uncoating conditions, leaving open the question of whether those models reflected genuine cellular biology. This study addresses that gap directly, though it remains anchored to a single serotype — echovirus 18 — and whether the precise mechanism generalizes across the broader enterovirus genus, which includes poliovirus, coxsackieviruses, and EV-D68, will require follow-on work. The findings are incremental in framing but potentially foundational in impact: atomic-resolution knowledge of the open-particle transition state creates a tractable target for small-molecule inhibitors designed to lock the capsid shut or prevent genome translocation. For the antiviral development pipeline, this represents a meaningful structural foothold rather than a clinical breakthrough.